Clinigen - FY 2020 results: stock now looks materially mispriced

Davy Research
/Read Important Disclosures

Today’s FY 2020 results reaffirmed the strong underlying growth indicated at the year-end trading update in July. Much improved working capital dynamics in H2 boosted cash conversion. Encouragingly, growth guidance has been reaffirmed for FY 2021 towards the lower end of the 5-10% range; although, likely to be more weighted towards H2 mainly given COVID-19. We expect to keep our FY 2021 and FY 2022 estimates broadly unchanged.